BioImpact discloses 5.6% stake in Climb Bio

BioImpact LLC filed a Schedule 13G reporting a significant passive stake in Climb Bio, Inc..

Accepted by SEC EDGAR 02/17/2026 - 04:09 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

BioImpact LLC filed a Schedule 13G reporting a significant passive stake in Climb Bio, Inc.. BioImpact beneficially owns 2,671,480 shares of Climb Bio common stock, representing 5.6% of the class as of 12/31/2025.

BioImpact has sole power to vote and dispose of all reported shares, with no shared voting or dispositive power. The filing states the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Climb Bio.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake in Climb Bio (CLYM) does BioImpact LLC report?

BioImpact LLC reports beneficial ownership of 2,671,480 Climb Bio common shares, representing 5.6% of the outstanding class. This holding gives BioImpact a notable minority position with sole voting and dispositive power over all reported shares.

Is BioImpact LLC’s Climb Bio (CLYM) position considered passive?

Yes. BioImpact certifies the shares were acquired and are held in the ordinary course of business, not to change or influence control of Climb Bio. The filing is on Schedule 13G, which is used for passive ownership reporting under SEC rules.

As of what date is BioImpact LLC’s 5.6% Climb Bio (CLYM) ownership measured?

BioImpact’s 5.6% beneficial ownership of Climb Bio common stock is measured as of December 31, 2025. The Schedule 13G uses this date to calculate the 2,671,480 shares as a percentage of the total class outstanding.

Does BioImpact LLC share voting or dispositive power over Climb Bio (CLYM) shares?

No. The filing states BioImpact has sole power to vote and sole power to dispose of all 2,671,480 reported shares. It reports zero shared voting power and zero shared dispositive power over Climb Bio common stock.

What type of security in Climb Bio (CLYM) is held by BioImpact LLC?

BioImpact holds Climb Bio’s common stock with a par value of $0.0001 per share. The CUSIP for this class is 28658R106, and the holding represents 5.6% of that common equity class as of December 31, 2025.

Who signed the Schedule 13G reporting BioImpact LLC’s Climb Bio (CLYM) stake?

The Schedule 13G was signed by Christopher Wolf as Chief Financial Officer on February 17, 2026. The signature certifies that the information about BioImpact LLC’s ownership of Climb Bio common stock is true, complete, and correct.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Climb Bio, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

28658R106

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 28658R106

1

Names of Reporting Persons

MPM BioImpact LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,671,480.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,671,480.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,671,480.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.6 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Climb Bio, Inc.
(b)	Address of issuer's principal executive offices: 20 William Street, Suite 145, Wellesley Hills, MA, 02481.
Item 2.
(a)	Name of person filing: MPM BioImpact LLC
(b)	Address or principal business office or, if none, residence: 399 Boylston Street, Suite 1100 Boston, MA 02116
(c)	Citizenship: Delaware
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 28658R106
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 2,671,480
(b)	Percent of class: 5.6%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 2,671,480
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 2,671,480
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

MPM BioImpact LLC

Signature:	Christopher Wolf
Name/Title:	Chief Financial Officer
Date:	02/17/2026